Anthelmintic Drugs for Repurposing against Gram-Negative Bacilli Infections

Author:

Smani Younes123ORCID,Canturri Andrea Miró12

Affiliation:

1. Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain

2. Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/ University of Seville, Seville, Spain

3. Department of Molecular Biology and Biochemical Engineering, Andalusian Center of Developmental Biology, CSIC, University of Pablo de Olavide, Seville, Spain

Abstract

: Bacterial infections are among the leading causes of death worldwide. The emergence of antimicrobial resistance factors threatens the efficacy of all current antimicrobial agents, with some already made ineffective, and, as a result, there is an urgent need for new treatment approaches. International organizations, such as the World Health Organization and the European Centre for Diseases Control, have recognized infections caused by multi-drug-resistant (MDR) bacteria as a priority for global health action. : Classical antimicrobial drug discovery involves in vitro screening for antimicrobial candidates, Structure-Activity Relationship analysis, followed by in vivo testing for toxicity. Bringing drugs from the bench to the bedside involves huge expenditures in time and resources. This, along with the relatively short window of therapeutic application for antibiotics attributed to the rapid emergence of drug resistance, has, at least until recently, resulted in a waning interest in antibiotic discovery among pharmaceutical companies. In this environment, “repurposing” (defined as investigating new uses for existing approved drugs) has gained renewed interest, as reflected by several recent studies, and may help to speed up the drug development process and save years of expensive research invested in antimicrobial drug development. : The goal of this review is to provide an overview of the scientific evidence on potential anthelmintic drugs targeting Gram-negative bacilli (GNB). In particular, we aim to: (i) highlight the potential of anthelmintic drugs for treatments of GNB infections, (ii) review their mechanisms of action against these bacteria, (iii) summarize the outcome of preclinical studies investigating approved anthelmintic drugs that target these bacteria, (iv) provide critical challenges for further anthelmintic repurposing drugs development, and (v) list the specific anthelmintic drugs that may be more likely to be repurposed.

Funder

Instituto de Salud Carlos III, Proyectos de Investigación en Salud

Ministerio de Economía y Competitividad of Spain

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference80 articles.

1. Tacconelli E.; Carrara E.; Savoldi A.; Harbarth S.; Mendelson M.; Monnet D.L.; Pulcini C.; Kahlmeter G.; Kluytmans J.; Carmeli Y.; Ouellette M.; Outterson K.; Patel J.; Cavaleri M.; Cox E.M.; Houchens C.R.; Grayson M.L.; Hansen P.; Singh N.; Theuretzbacher U.; Magrini N.; Aboderin A.O.; Al-Abri S.S.; Awang Jalil N.; Benzonana N.; Bhattacharya S.; Brink A.J.; Burkert F.R.; Cars O.; Cornaglia G.; Dyar O.J.; Friedrich A.W.; Gales A.C.; Gandra S.; Giske C.G.; Goff D.A.; Goossens H.; Gottlieb T.; Guzman Blanco M.; Hryniewicz W.; Kattula D.; Jinks T.; Kanj S.S.; Kerr L.; Kieny M-P.; Kim Y.S.; Kozlov R.S.; Labarca J.; Laxminarayan R.; Leder K.; Leibovici L.; Levy-Hara G.; Littman J.; Malhotra-Kumar S.; Manchanda V.; Moja L.; Ndoye B.; Pan A.; Paterson D.L.; Paul M.; Qiu H.; Ramon-Pardo P.; Rodríguez-Baño J.; Sanguinetti M.; Sengupta S.; Sharland M.; Si-Mehand M.; Silver L.L.; Song W.; Steinbakk M.; Thomsen J.; Thwaites G.E.; van der Meer J.W.M.; Van Kinh N.; Vega S.; Villegas M.V.; Wechsler-Fördös A.; Wertheim H.F.L.; Wesangula E.; Woodford N.; Yilmaz F.O.; Zorzet A.; Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018,18(3),318-327

2. O’ Neill J.; Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial resistance 2016

3. Antimicrobial resistance. Available from: (Accessed date:17 November 2021).2021

4. Viderman D.; Brotfain E.; Khamzina Y.; Kapanova G.; Zhumadilov A.; Poddighe D.; Bacterial resistance in the intensive care unit of developing countries: Report from a tertiary hospital in Kazakhstan. J Glob Antimicrob Resist 2019,17,35-38

5. Simeon P.; Godman B.; Kalemeera F.; Antibiotics’ susceptibility patterns of bacterial isolates causing lower respiratory tract infections in ICU patients at referral hospitals in Namibia. Hosp Pract 2021,49(5),356-363

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3